Amgen (NASDAQ:AMGN) executives highlighted broad-based growth in 2025 and laid out expectations for continued momentum in ...
Amgen Inc. delivered strong operational performance across the board in 2025, and you can see that in the breadth of our business. Three of these, Repatha, Evenity, and TestSpire, all grew by more ...
Investor's Business Daily on MSN
Amgen eyes buy zone after fourth-quarter beat as obesity studies mount
Amgen is running a number of studies of its obesity drug, MariTide.
By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...
Amgen Inc. reports fourth-quarter earnings today after the bell, putting the spotlight on how the $185.6 billion biotechnology giant plans to navigate a year marked by significant biosimilar ...
Looking ahead, Amgen issued 2026 guidance with revenue projected between $37.0 billion and $38.4 billion, compared to the consensus estimate of $37.1 billion. The company expects adjusted EPS of ...
Zacks Investment Research on MSN
Silver economy boom: Investing in healthcare's aging tailwinds
An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...
For the quarter ended December 2025, Amgen (AMGN) reported revenue of $9.87 billion, up 8.6% over the same period last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results